What is LEADR and How Can It Help with Lupus Management?
The Lupus Engagement through Activity and Digital Resources (LEADR) intervention implements a digital health coaching program to increase physical activity among African American women and Latinas with lupus. LEADR uses a culturally and linguistically appropriate digital coaching program to increase physical activity among lupus patients as a powerful self-management tool. Our focus area is Georgia.
African American or Black and Hispanic or Latina women with Lupus
Evaluating Digital Health Coaching for Lupus Management
The goal of this study is to evaluate how digital health coaching affects the exercise habits, health, and well-being of Black, African American, and/or Latina women with systemic lupus erythematosus referred to as SLE or lupus.
Participants will be randomly assigned to either receive standard care and a digital education packet or be assigned a health coach. All participants involved in the study will receive a FREE Fitbit Inspire and will be asked to use it to track daily activity.
Patient-reported outcomes will be collected periodically throughout the study via surveys and qualitative interviews to assess study results.
Participants who do not receive coaching will receive an additional $20 Amazon gift card (total of two gift cards) for data collection at the beginning and end of the study.
To enroll in the study or check eligibility:
All study activities are conducted over the phone or virtually.
Age 18 and older
Ability to speak and read English
Diagnosed with systemic lupus erythmatosus (SLE)
Black, African American, and/or Latina women
Internet access via smartphone, tablet, or computer
Ability to receive calls, texts, emails, and electronic study assessments
Not currently participating in another lupus support program
Office of Minority Health (OMH) Funding Note
The production of this activity was supported by Grant Number MP-CPI- 15-001 from the U.S. Department of Health and Human Services Office of Minority Health (HHS, OMH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS, OMH. 1 CPIMP201213-01-00, CFDA number 93.137 No commercial support was obtained.